// Biotech and Pharma Therapeutics
Who Should be Brought Into the Conversation Around Women’s Health?
October 22, 2025 / women’s health equity / menopause care access / employer health benefits / FDA women’s treatments / healthcare gender disparities
At HLTH 2025, leaders stressed the urgent need to involve employers, media, and men in advancing women’s health equity—highlighting provider shortages, biased coverage, and underinsurance of FDA-approved treatments as systemic issues needing broad-based advocacy and reform.
Boston Scientific continues to win in electrophysiology
October 22, 2025 / pulsed field ablation / atrial fibrillation treatment / electrophysiology market growth / Boston Scientific Farapulse / medtech cardiac innovation
Boston Scientific’s electrophysiology sales surged 64% in Q3, driven by adoption of its pulsed field ablation (PFA) technology, Farapulse—an innovative atrial fibrillation treatment now central to a competitive medtech race reshaping standards in cardiac care.
Takeda bulks up oncology portfolio via deal with Innovent
October 22, 2025 / Takeda oncology pipeline / Innovent Biologics partnership / solid tumor therapies / non-small cell lung cancer / gastric cancer treatment
Takeda has partnered with Innovent Biologics to co-develop and commercialize two late-stage oncology candidates—IBI363 and IBI343—targeting solid tumors, including lung, colorectal, gastric, and pancreatic cancers, strengthening its global oncology pipeline outside Greater China.
Forget fiber. Science just found the foods that really help constipation
October 22, 2025 / chronic constipation diet / kiwifruit for digestion / evidence-based nutrition / constipation treatment guidelines / personalized gut health
New evidence-based guidelines from King’s College London identify kiwifruit, rye bread, and mineral-rich water as effective for chronic constipation, challenging outdated fiber-heavy advice and offering clinicians clearer, personalized dietary tools for managing this burdensome condition.
Providence teams up with Humana for VBC data exchange
October 21, 2025 / value-based care / healthcare interoperability / FHIR data standards / Providence Humana partnership / Medicare Advantage integration
Providence and Humana have launched a scalable, FHIR-based data exchange initiative to improve value-based care delivery through streamlined, secure interoperability—enhancing care coordination, reducing administrative burden, and aligning with evolving CMS interoperability regulations.
// 4th Industrial Revolution
AI-driven eye screening aims to close the diabetic vision gap in community clinics
A new randomized trial at San Ysidro Health tests autonomous AI-driven diabetic retinopathy screening in community clinics, aiming to boost screening rates, accelerate diagnosis, and improve care access for underserved patients directly at the point of care.
Smarter insulin pump systems help stabilize glucose in young patients, study reveals
October 22, 2025 / type 1 diabetes / hybrid closed-loop insulin pump / pediatric glycemic control / diabetes technology / hypoglycemia prevention
A Polish study found that children with type 1 diabetes using advanced hybrid closed-loop insulin pumps achieved superior glucose stability compared to those with predictive low glucose suspend systems, highlighting the technology’s benefits despite persistent dietary challenges.
New computer model lets researchers simulate how brain circuits make decisions
October 22, 2025 / brain circuit modeling / cognitive flexibility simulation / psychiatric disorder research / decision-making neuroscience / schizophrenia brain pathways
Researchers developed CogLinks, a biologically grounded computer model that simulates brain circuit decision-making, revealing how disrupted connections—like between the prefrontal cortex and mediodorsal thalamus—impair cognitive flexibility, offering insights into psychiatric disorders like schizophrenia and OCD.
WestCX rolls out agentic AI platform for pharmacies
October 22, 2025 / pharmacy AI platform / medication adherence tools / agentic AI healthcare / pharmacy automation solutions / patient communication technology
WestCX has launched an agentic AI platform to automate pharmacy-patient communications, improving medication adherence, reducing call volume, and enhancing operational efficiency—supporting front-line pharmacy teams through personalized, compliant, and scalable engagement across Mosaicx and TeleVox platforms.
Oscar Health introduces a suite of health plans and AI features
October 22, 2025 / AI healthcare assistant / menopause health plan / chronic disease management / personalized health coverage / Oscar Health innovation
Oscar Health launched new AI-driven tools and tailored health plans—including Oswell for personalized care navigation and HelloMeno for menopause support—aimed at enhancing symptom management, medication access, and cost transparency for chronic and gender-specific health conditions.
// Business & Markets
CMS’ New $50B Rural Health Fund — Is It Just Another Band-Aid?
CMS’ $50B Rural Health Transformation Program aims to stabilize rural healthcare through state-driven reforms, but experts warn it may not fully address systemic challenges like hospital closures, workforce shortages, and overreliance on public reimbursement.
Google teams up with b.well Connected Health
Google and b.well Connected Health have partnered to enhance personalized, interoperable healthcare by aggregating patient data from medical records, wearables, and financial sources—enabling secure, real-time insights and advancing AI-driven, patient-centered care experiences at scale.
New York earmarks $2.6 billion to modernize hospital EHRs
October 22, 2025 / EHR modernization funding / safety net hospitals / New York healthcare investment / hospital infrastructure upgrade / digital health transformation
New York State is investing $2.6 billion to modernize EHR systems and infrastructure at safety net hospitals, aiming to enhance care delivery, expand access, and ensure long-term sustainability through strategic partnerships and upgraded digital health capabilities.
CoMind raises $102.5M to develop non-invasive bedside brain monitor
CoMind raised $102.5M to develop a non-invasive bedside brain monitor using Lidar-inspired tech to measure cerebral blood flow and oxygenation in real time, aiming to improve diagnosis and treatment of neurological conditions like stroke and traumatic brain injury.
Intuitive Surgical reports strong Q3 as da Vinci procedures climb
Intuitive Surgical reported strong Q3 growth, with da Vinci robotic procedures rising 20% year-over-year and revenue reaching $2.51B. Increased adoption of the da Vinci 5 system and lung biopsy platform fueled performance, exceeding analyst expectations.
// Legal & Regulatory
Immusoft Receives FDA Fast Track Designation for ISP-001, a First-in-Class Engineered B Cell Therapy for MPS I
October 21, 2025 / engineered B cell therapy / MPS I treatment / FDA Fast Track ISP-001 / rare disease gene therapy
Immusoft’s ISP-001, a first-in-class engineered B cell therapy for MPS I, received FDA Fast Track designation. The therapy enables sustained enzyme delivery, showing early safety and functional benefits, potentially transforming treatment for this rare lysosomal storage disorder.
Boehringer’s Jascayd follows up US approval with Chinese nod
Boehringer Ingelheim’s Jascayd (nerandomilast) received approval in China for idiopathic pulmonary fibrosis, following recent U.S. FDA clearance. It marks the first new IPF treatment in over a decade, showing strong efficacy and improved tolerability.
Tezspire approved in the EU for chronic rhinosinusitis with nasal polyps
The European Commission approved Tezspire (tezepelumab) as an add-on treatment for severe chronic rhinosinusitis with nasal polyps (CRSwNP), following strong Phase III data showing reduced polyp severity, corticosteroid use, and surgical need in patients unresponsive to standard therapies.
Regeneron settles Eylea patent dispute with Celltrion, allowing another biosimilar to launch at end of 2026
October 22, 2025 / Eylea Biosimilar Launch / Regeneron Celltrion Settlement / Eydenzelt FDA Approval
Regeneron settled its Eylea (aflibercept) patent dispute with Celltrion, allowing the biosimilar Eydenzelt to launch in the U.S. by December 2026. This adds to growing biosimilar competition for Eylea, which continues to face declining U.S. sales.
Replimune Announces FDA Acceptance of BLA Resubmission of RP1 for the Treatment of Advanced Melanoma
October 20, 2025 / RP1 Melanoma Treatment / FDA Immunotherapy Review / Anti-PD-1 Resistant Melanoma
The FDA has accepted Replimune’s resubmitted BLA for RP1, an oncolytic immunotherapy combined with nivolumab, targeting advanced melanoma in patients resistant to PD-1 therapy. A PDUFA decision is expected by April 10, 2026.
// Research & Development
A “toxic duo” may be the hidden trigger behind Alzheimer’s disease
October 22, 2025 / amyloid beta fibrinogen / Alzheimer’s Disease Trigger / Blood-brain barrier damage
New research reveals that a complex formed by amyloid beta and fibrinogen triggers early Alzheimer’s damage by promoting resistant clots, inflammation, and blood-brain barrier disruption—highlighting a promising therapeutic target for preventing neurodegeneration through vascular protection.
Moderna scraps congenital virus program after vaccine shows little protective effect in phase 3
October 22, 2025 / Moderna CMV vaccine / mRNA-1647 Phase 3 failure / congenital CMV prevention / cytomegalovirus clinical trial / mRNA vaccine development
Moderna has discontinued its congenital cytomegalovirus (CMV) vaccine program after mRNA-1647 failed to prevent primary infection in a large Phase 3 trial. The company will shift focus to cancer vaccines and ongoing CMV studies in transplant patients.
Ingestible capsule developed for the diagnosis of acute mesenteric ischemia
October 22, 2025 / acute mesenteric ischemia / ingestible diagnostic capsule / FIREFLI bioluminescence sensor / noninvasive GI diagnostics / smart capsule technology
Researchers developed and validated FIREFLI, an ingestible bioluminescent capsule that noninvasively detects acute mesenteric ischemia by sensing reduced intestinal perfusion, showing 98% sensitivity in preclinical trials—offering a faster, safer diagnostic alternative to current invasive imaging methods.
Sanofi drug acquired in buyout succeeds in rare disease trial
Sanofi’s recombinant protein therapy, efdoralprin alfa, met primary and secondary endpoints in a Phase 2 trial for alpha-1 antitrypsin deficiency (AATD), offering a less frequent, non-plasma alternative to current treatments with improved AAT protein levels and safety profile.
Arcturus’ stock halves after mRNA therapy fails to evoke efficacy in cystic fibrosis trial
October 22, 2025 / ARCT-032 Cystic Fibrosis / mRNA therapy lung function / inhaled CF treatment / mucus plug reduction
Arcturus’ inhaled mRNA therapy ARCT-032 showed no meaningful lung function improvement in a Phase 2 CF trial but demonstrated safety and early signs of mucus reduction, prompting continued development with higher dosing and longer treatment duration.
// Politics
Anti-science bills hit statehouses, stripping away public health protections built over a century
Over 420 anti-science bills targeting public health measures—such as vaccines, fluoride, and milk safety—have been introduced in U.S. states, threatening long-established protections and potentially undermining national health infrastructure, according to an AP investigation.
Trump admin readies ‘imminent’ probe into other nations’ drug pricing, raising new tariff threat: FT
October 22, 2025 / pharmaceutical tariffs threat / Trump drug pricing probe / US drug cost reform
The Trump administration is preparing a Section 301 investigation into foreign drug pricing, potentially leading to new pharmaceutical tariffs. This move intensifies efforts to align U.S. drug costs with global prices, creating uncertainty for biopharma companies amid ongoing MFN negotiations.
AHA urges tariff exceptions for certain PPE, medical devices
October 21, 2025 / medical device tariffs / PPE import restrictions / AHA tariff exemption request
The American Hospital Association is urging the Trump administration to exempt critical medical devices and PPE from potential Section 232 tariffs, warning such trade restrictions could disrupt care delivery, raise costs, and threaten already fragile healthcare supply chains.
MDMA warns Section 232 tariffs could hurt US medtech manufacturing
October 21, 2025 / Section 232 tariffs / Medical device imports / MDMA trade policy / US medtech manufacturing
The Medical Device Manufacturers Association warns that Section 232 tariffs on imported medical technologies could disrupt global medtech supply chains, raise costs, hinder U.S. manufacturing, and weaken export competitiveness—while failing to meaningfully enhance national security or supply resiliency.
Mark Cuban says Cost Plus Drugs will partner with TrumpRx
October 20, 2025 / Cost Plus Drugs partnership / TrumpRx drug pricing / Mark Cuban pharmacy model
Mark Cuban announced that Cost Plus Drugs will join TrumpRx, a drug pricing transparency tool enabling consumers to compare direct-to-consumer prescription prices. The partnership aims to reduce costs and challenge pharmacy benefit managers’ influence on U.S. drug pricing.